On this page
What is Cystic Fibrosis?
Cystic fibrosis (CF), also known as mucoviscidosis, is a complex, life-limiting genetic disease that affects multiple organ systems simultaneously. It is particularly damaging to the lungs and digestive system, where it causes severe functional impairment.
CF is a hereditary condition that affects the cells responsible for producing bodily secretions, including:
- Mucus
- Sweat
- Saliva
- Digestive juices (pancreatic secretions)
In healthy individuals, these secretions are thin and fluid, acting as lubricants and protective barriers. In people with cystic fibrosis, a defective gene causes these secretions to become abnormally thick and sticky. Rather than performing their normal lubricating function, these viscous secretions clog ducts, channels, and passageways, particularly in the pancreas and lungs.
Why Is CF So Serious?
The most dangerous consequence of cystic fibrosis is progressive respiratory failure due to chronic lung damage. Additionally, thick secretions block the pancreatic ducts, preventing digestive enzymes from reaching the intestine. This impairs the body’s ability to absorb fats, proteins, and fat-soluble vitamins, leading to significant nutritional deficiencies that manifest from early infancy.
A note of hope: In recent years, the development of innovative molecular therapies, particularly CFTR modulators, has fundamentally transformed the course of cystic fibrosis. These therapies enable treatment of the underlying genetic defect rather than merely its symptoms.
Life Expectancy
The life expectancy of people with cystic fibrosis has improved dramatically over the past several decades, driven by advances in early diagnosis, comprehensive care, and most recently, targeted molecular therapies.
- In the 1950s, most children with CF did not survive beyond elementary school age.
- By the 1980s–1990s, median survival had extended into the late 20s and 30s.
- Today, statistical projections indicate that newborns diagnosed with CF can expect to live well into their sixth decade of life, and potentially beyond, with a quality of life that would have been unimaginable just two decades ago.
The introduction of CFTR modulator therapies (such as elexacaftor/tezacaftor/ivacaftor) has been particularly transformative, with many patients experiencing near-normalization of lung function and a dramatic reduction in disease burden.
Pregnancy and Family Planning
If you are pregnant or trying to conceive, it is worth discussing carrier testing for cystic fibrosis with your doctor, both for yourself and your partner. While in the past this screening was recommended only for couples with a known family history of CF, current guidelines recommend genetic carrier testing for all couples planning a pregnancy.
What Does Carrier Testing Involve?
The test is performed in a laboratory on a blood or saliva sample and can determine whether either partner carries a mutation in the CFTR gene. Being a carrier (having one defective copy of the gene) does not cause cystic fibrosis in the carrier themselves, but it can be passed on to children.
What If Both Partners Are Carriers?
If both parents are carriers of a CFTR mutation, with each pregnancy there is:
- 25% probability the child will have cystic fibrosis (inherits two defective copies)
- 50% probability the child will be a carrier (inherits one defective copy) but will be healthy
- 25% probability the child will be neither affected nor a carrier
If the fetus is identified as being at high risk, the physician may recommend prenatal diagnostic testing (e.g., amniocentesis or chorionic villus sampling) to confirm whether the baby has CF.
Important: Cystic fibrosis cannot be treated before birth. The purpose of prenatal testing is to provide information to help families plan for the future and ensure optimal care from the moment of delivery.
The decision to undergo CF carrier screening is deeply personal and may be influenced by individual values, religious beliefs, and risk assessment. Additionally, not all CFTR mutations can be detected by current panels. In rare cases, a carrier status may be missed, though this probability is very low.
Causes
In cystic fibrosis, a defective gene, known as the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator), alters the structure and function of a protein that normally regulates the movement of sodium chloride (salt) across cell membranes. When this protein malfunctions, cells cannot properly control the balance of salt and water on their surfaces, resulting in:
- Abnormally thick and viscous mucus in the airways, digestive tract, and reproductive system
- Excessively salty sweat (a characteristic feature exploited in the diagnostic sweat test)
How Is CF Inherited?
Cystic fibrosis follows an autosomal recessive inheritance pattern:
- The defective gene is recessive, meaning a person must inherit two defective copies (one from each parent) to develop the disease.
- Individuals who inherit only one defective copy will not develop CF but will become carriers. They are healthy but can pass the mutation to their children.
- Over 2,000 different mutations of the CFTR gene have been identified, with the most common being the ΔF508 (delta-F508) deletion.
Parents often experience guilt when a child is diagnosed with cystic fibrosis. It is essential to emphasize that CF is not caused by any conscious choice or behavior on the part of parents. It is a consequence of inherited genetic variation, and carriers are perfectly healthy individuals who could not have known they carried the mutation without genetic testing.
The Role of Fatty Acids
Some researchers have identified a potential role of essential fatty acid imbalances in cystic fibrosis:
- Individuals with CF tend to have elevated levels of arachidonic acid (a pro-inflammatory omega-6 fatty acid) and reduced levels of docosahexaenoic acid (DHA), an essential omega-3 fatty acid.
- Carriers of a single CFTR mutation show intermediate fatty acid levels, between those of affected patients and those without any mutation.
The exact relationship between fatty acid metabolism and the CFTR genetic defect remains under investigation, but it represents an area of active research with potential therapeutic implications.
Risk Factors
The single greatest risk factor for cystic fibrosis is family history:
- If both partners in a couple come from families with CF cases, or are known carriers, their children have a 1 in 4 chance of being affected
- Ethnicity also plays a role. CF is more prevalent among individuals of Northern European descent, affecting approximately 1 in 2,500–3,500 newborns in these populations. It is less common but not absent in other ethnic groups.
Symptoms
The signs and symptoms of cystic fibrosis vary considerably depending on:
- The severity of the disease (which correlates in part with the specific genetic mutations involved)
- The organ systems primarily affected (some children primarily have lung disease, others primarily digestive issues, and many have both)
- The age of the patient (symptoms evolve over time)
Symptoms in Newborns
In some newborns, the first sign of cystic fibrosis is meconium ileus, a bowel obstruction caused by excessively thick and sticky meconium (the dark greenish-black stool normally passed during the first day or two of life) that blocks the intestine. This is a medical emergency requiring immediate surgical or endoscopic intervention.
Other early signs in newborns include:
- Failure to thrive (poor weight gain and growth despite adequate feeding).
- Fatty, bulky, foul-smelling stools (steatorrhea): a sign of fat malabsorption due to pancreatic insufficiency.
- Frequent respiratory infections, even in the first weeks of life.
Symptoms in Children and Adolescents
As the child grows, the clinical picture becomes more evident. Key symptoms include:
Characteristic signs:
- Salty-tasting skin: Parents often notice a salty taste when kissing their baby, which is one of the earliest and most recognizable signs of CF. This results from an abnormally high salt concentration in sweat.
- Clubbing of fingers and toes (hippocratic fingers or drumstick digits): Rounding and enlargement of the fingertips and toenails, developing progressively in most CF patients due to chronic low oxygen levels.
Gastrointestinal symptoms:
- Intestinal blockage may recur throughout childhood
- Greasy, foul-smelling stools from persistent fat malabsorption
- Rectal prolapse: Protrusion of part of the rectum through the anus, caused by straining with stools or chronic cough
- Growth retardation: a child consistently falls below expected growth percentiles, especially when combined with other symptoms
- In children over 4 years: intussusception (telescoping of one portion of the intestine into another)
Respiratory symptoms:
- Very thick, viscous mucus/phlegm. Children tend to swallow rather than spit phlegm, so parents may not notice this directly.
- Chronic cough often productive, sometimes resembling asthma.
- Frequent upper respiratory tract infections and sinus infections, complicated by recurrent pneumonia or bronchitis.
Additional associated conditions:
- Nasal polyps
- Liver cirrhosis from bile duct inflammation or obstruction
Risks and Complications
Respiratory Complications
Respiratory disease is the primary cause of morbidity and mortality in cystic fibrosis. Chronic airway obstruction from thick mucus creates an ideal environment for bacterial colonization and infection.
Common respiratory complications include:
- Pneumonia (recurrent and progressively damaging)
- Chronic bronchitis
- Chronic sinusitis
- Bronchiectasis: Permanent, abnormal widening of the bronchial walls caused by chronic infection and inflammation, which further impairs airway clearance
- Bronchial asthma: Arising from chronic bronchial wall inflammation
The key pathogen most commonly responsible for pulmonary infections in CF patients is Pseudomonas aeruginosa, a bacterium that rarely infects healthy individuals but thrives in the mucus-filled airways of CF patients. While antibiotics can reduce the frequency and severity of infections, Pseudomonas is never completely eradicated from the airways once established.
More severe respiratory complications include:
- Hemoptysis: Coughing up blood from damaged lung blood vessels
- Respiratory failure: Progressive loss of lung function requiring oxygen support or ventilation
- Pneumothorax: Collapsed lung due to air leaking into the chest cavity through a rupture in the lung surface
- Cor pulmonale: Right-sided heart failure resulting from chronic pulmonary hypertension, a life-threatening late complication
Nutritional Complications
The nutritional consequences of CF can be severe and begin in infancy:
-
Pancreatic insufficiency: Thick secretions block the pancreatic ducts, preventing digestive enzymes from reaching the intestine. This causes chronic malabsorption of fats and proteins and inability to absorb fat-soluble vitamins:
- Vitamin A: essential for vision and immune function
- Vitamin D: supports bone health and immune modulation
- Vitamin E: antioxidant protection
- Vitamin K: blood clotting
-
Cystic Fibrosis-Related Diabetes (CFRD): The pancreas also regulates blood glucose. Progressive pancreatic damage leads to diabetes in approximately 20% of CF patients: a distinct form that differs from both type 1 and type 2 diabetes.
-
Biliary cirrhosis: Bile duct obstruction leads to liver inflammation, cholecystitis, and potentially severe liver damage
-
Chronic diarrhea and growth failure
Reproductive System Complications
In males: The thick secretions frequently obstruct the vas deferens (the duct connecting the testes to the urethra), leading to obstructive azoospermia, the absence of sperm in the ejaculate. This affects the vast majority of men with CF, making them infertile through natural conception. However, sperm retrieval techniques (e.g., testicular sperm extraction, TESE) combined with in vitro fertilization (IVF) allow many men with CF to become biological fathers.
In women: CF can reduce fertility due to thickened cervical mucus impairing sperm transport. However, many women with CF can conceive and carry pregnancies successfully. Important considerations include:
- Pregnancy may worsen respiratory symptoms and nutritional status, so a careful risk-benefit assessment with specialists is essential before attempting conception.
- Hormonal contraception (pill, patch, ring) may worsen some CF symptoms in certain patients; contraceptive choices should always be discussed with both the gynecologist and the CF specialist.
When to See a Doctor
When to Suspect Cystic Fibrosis
Consult your doctor promptly if your child shows any of the following signs. Even though newborn screening (mandated in most countries) should ideally identify CF before symptoms appear:
In newborns and infants:
- Poor growth despite adequate feeding
- Chronic respiratory problems, particularly recurrent pneumonia
- Frequent episodes of large, greasy, foul-smelling stools
- Salty-tasting skin
In older children:
- Recurrent diarrhea or fatty stools
- Frequent respiratory infections, including pneumonia
- Insufficient growth not following the expected growth percentile curve, particularly when combined with other signs
When to Seek Medical Attention for Complications
Contact your doctor immediately if, after a CF diagnosis, your child develops:
- Fever (suggesting a new or worsening infection)
- Worsening cough or increased sputum production
- Breathing difficulties (increased respiratory rate, use of accessory muscles, blue lips)
- Increased fatigue or unusual weakness
- Decreased appetite or significant weight loss
Ongoing care: Children with CF should have regular appointments at a specialized CF center, in addition to routine visits with their pediatrician or family doctor for prescription management and monitoring of respiratory and digestive health.
Diagnosis
The diagnostic pathway for cystic fibrosis has evolved to ensure the earliest possible detection, which is critical for initiating treatment before irreversible organ damage occurs.
Newborn Screening
In many countries, newborn screening for cystic fibrosis is performed on all babies within the first days of life. The procedure involves:
- Blood sample collection via heel-prick (the same sample used for other newborn metabolic screening tests)
- Measurement of Immunoreactive Trypsinogen (IRT): A pancreatic protein that is elevated in newborns with CF due to blocked pancreatic ducts
- If IRT is elevated: First-level genetic analysis to identify the most common CFTR mutations
A positive screening result does not confirm CF; it indicates the need for confirmatory testing.
The Sweat Test
Despite decades of advances in molecular diagnostics, the sweat chloride test remains the gold standard for confirming a CF diagnosis.
How it works:
- Pilocarpine iontophoresis: A small amount of pilocarpine (a sweat-stimulating drug) is applied to a small area of the forearm using a low-level electrical current. This is a painless procedure.
- Sweat collection: The produced sweat is collected and analyzed for chloride concentration.
Interpretation of results:
| Sweat Chloride Level | Interpretation |
|---|---|
| ≥ 60 mmol/L | Consistent with CF diagnosis |
| 30–59 mmol/L | Borderline requires further investigation |
| < 30 mmol/L | CF unlikely |
The test should be performed in a certified laboratory with adequate sweat volume collected. Results in the borderline range require repeat testing and advanced diagnostic workup.
Genetic Analysis and Advanced Testing
DNA analysis is essential not only for confirming the diagnosis but also for identifying the specific CFTR mutation(s) present in the patient. This is now clinically critical because:
- Eligibility for CFTR modulator therapies (the most transformative treatments available) depends on the specific mutation.
- There are over 2,000 known CFTR mutations. Standard diagnostic panels cover the most common ones, but comprehensive sequencing may be needed in atypical cases.
Advanced functional tests may be performed in diagnostically uncertain cases:
- Nasal Potential Difference (NPD) measurement: Measures the electrical potential across the nasal epithelium to assess CFTR channel function directly.
- Intestinal Current Measurement (ICM): Performed on a rectal biopsy specimen, this test evaluates chloride channel function in intestinal epithelial cells. It is useful when sweat test and genetics are inconclusive.
Treatment
Modern CF treatment has ambitious goals that go far beyond symptom management. The objectives now include:
- Restoring CFTR protein function at the molecular level.
- Preserving lung function and preventing irreversible damage.
- Optimizing nutritional status for normal growth and development.
- Maximizing quality of life across all age groups.
Treatment is multidisciplinary, requiring the coordinated expertise of pulmonologists, gastroenterologists, dietitians, physiotherapists, psychologists, and specialist CF nurses. It also demands daily commitment from patients and families.
CFTR Protein Modulators
CFTR modulators represent the most significant therapeutic revolution in CF history. Unlike all previous treatments, which addressed the consequences of the disease, these drugs target the underlying molecular defect, directly helping the defective CFTR protein to work better.
Types of modulators:
- Potentiators (e.g., ivacaftor): Help the CFTR protein that reaches the cell surface to open and function properly.
- Correctors (e.g., tezacaftor, elexacaftor): Help the misfolded CFTR protein reach the cell surface in the first place.
- Combination therapy: elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio): The most effective currently available combination, approved for patients aged 2 and older with at least one ΔF508 mutation (covering approximately 90% of CF patients). Clinical trials have shown:
- Improvement in lung function (FEV₁) of 10–15 percentage points on average.
- Up to 40% reduction in pulmonary exacerbations.
- Significant weight gain and nutritional improvement.
- Dramatic reduction in hospitalization rates.
Note: Not all patients are eligible for all modulators. Eligibility depends on the specific CFTR mutation(s) identified through genetic testing.
Managing Respiratory Complications
Even with modulator therapy, airway clearance remains a cornerstone of CF management to prevent mucus stagnation and recurrent infections:
Physiotherapy and airway clearance:
- Chest physiotherapy techniques: Manual percussion or use of positive expiratory pressure (PEP) devices and oscillating PEP (e.g., Flutter, Acapella) to mobilize secretions.
- Active Cycle of Breathing Techniques (ACBT): A structured breathing technique widely used in CF management.
- Autogenic drainage: A self-administered breathing technique using different lung volumes to progressively mobilize secretions from peripheral to central airways.
Inhaled medications:
- Dornase alfa (DNase): An enzyme that cleaves extracellular DNA, a major contributor to mucus viscosity, making secretions thinner and easier to expectorate. Usually inhaled via nebulizer before physiotherapy.
- Hypertonic saline: Inhaled to rehydrate airway surfaces and improve mucociliary clearance.
- Bronchodilators (e.g., salbutamol): Administered via aerosol to keep airways open before physiotherapy sessions.
Antibiotic therapy:
- Acute exacerbations: Treated with intensive intravenous antibiotic courses (often in hospital or at home) targeting specific organisms.
- Chronic suppression therapy: Inhaled antibiotics (e.g., tobramycin, aztreonam) used on alternating months or continuously to control chronic Pseudomonas aeruginosa colonization.
- Anti-inflammatory therapy: Low-dose azithromycin (a macrolide antibiotic with immunomodulatory properties) is widely used for its ability to reduce airway inflammation and exacerbation frequency.
Nutritional and Enzyme Support
Optimizing nutrition is as important as treating lung disease. Malnutrition is directly linked to worse pulmonary outcomes in CF.
Pancreatic enzyme replacement therapy (PERT):
- Enteric-coated pancreatic enzymes (lipase, protease, amylase) must be taken with every meal and snack to enable fat and protein digestion.
- Dosing is individualized based on fat intake and stool characteristics.
Vitamin supplementation:
- Fat-soluble vitamins (A, D, E, K) in specialized CF-formulations must be supplemented daily, as absorption through diet alone is insufficient.
- Regular monitoring of blood vitamin levels guides dosing adjustments.
Caloric requirements:
- CF patients typically require 120 to 150% of the calories needed by unaffected peers of the same age and size due to the combined energy demands of chronic lung disease, frequent infections, and malabsorption.
- When oral intake is insufficient, enteral nutrition via nasogastric or gastrostomy tube may be needed, particularly in children with growth failure.
CFRD management:
- Cystic fibrosis-related diabetes requires insulin therapy (unlike typical type 2 diabetes, it does not respond well to oral hypoglycemic agents) along with a carefully managed high-calorie diet
Organ Transplantation
When pulmonary disease reaches end-stage and medical therapies are no longer sufficient to maintain adequate oxygen levels and quality of life, bilateral lung transplantation offers a life-saving option for eligible patients.
Key considerations:
- Lung transplantation does not cure cystic fibrosis; the new lungs do not carry the CFTR mutation, but CF continues to affect the sinuses, pancreas, and other organs
- Median survival post-transplant is approximately 5–10 years, with some patients surviving 20+ years.
- Transplantation requires lifelong immunosuppressive therapy with its associated risks.
- Patient selection is rigorous, based on lung function decline rate, functional status, and absence of certain contraindications (e.g., specific multi-resistant bacteria).
Liver transplantation is occasionally performed in the small subset of patients who develop severe biliary cirrhosis.
Lifestyle and Daily Management
Physical exercise is considered an integral component of CF therapy, not merely a lifestyle recommendation.
- Regular aerobic exercise promotes mucus clearance, independently of physiotherapy.
- Improves cardiovascular fitness and aerobic capacity.
- Enhances bone density (important given the high prevalence of osteoporosis in CF).
- Has significant positive effects on mood, mental health, and self-esteem.
Infection prevention:
- Frequent handwashing: a critical and non-negotiable measure
- Cross-infection prevention between CF patients: CF patients should avoid close contact with other CF patients due to the risk of exchanging multi-resistant bacteria (particularly Burkholderia cepacia complex and MRSA). This means separate clinic waiting rooms, no CF patient support groups in person, and caution in social settings.
Hydration and electrolytes:
- Maintaining adequate fluid intake is essential at all times
- During summer or intensive physical activity, CF patients must supplement salt (sodium chloride) lost through abnormally salty sweat to prevent electrolyte imbalances
The Future: Gene Therapy and Genome Editing
Research into gene therapy and genome editing (particularly CRISPR/Cas9 technology) is advancing rapidly with the long-term goal of permanently correcting the CFTR genetic defect in lung stem cells. This development could one day lead to a true cure for cystic fibrosis. While not yet clinically available, early-phase trials are underway and results are promising.
Frequently Asked Questions
What is cystic fibrosis?
Cystic fibrosis is a serious hereditary genetic disease caused by mutations in the CFTR gene, which controls salt and water movement across cell membranes. The result is the production of abnormally thick and sticky mucus that blocks airways and digestive passages, causing progressive lung damage and nutritional deficiencies.
What are the main symptoms? When should I suspect cystic fibrosis?
Symptoms vary between patients and evolve over time. Key warning signs include:
- In newborns: Salty-tasting skin, meconium ileus (intestinal blockage at birth), poor weight gain, fatty stools
- In older children and adolescents: Accumulation of thick mucus in the airways, recurrent respiratory infections (especially pneumonia), chronic greasy diarrhea with foul-smelling stools, intestinal blockages, abdominal bloating, and growth retardation due to malabsorption
Any child showing a combination of chronic respiratory problems, poor growth, and gastrointestinal issues should be evaluated promptly for cystic fibrosis.
How is cystic fibrosis treated?
Cystic fibrosis currently has no definitive cure; it is a lifelong genetic condition. However, modern treatment has transformed it from a rapidly fatal childhood disease into a manageable chronic condition with an increasingly normal life expectancy. Treatment includes:
- CFTR modulator drugs: These target the genetic defect itself and dramatically improve lung function in eligible patients
- Daily airway clearance physiotherapy
- Inhaled medications (mucolytics, antibiotics, bronchodilators)
- Pancreatic enzyme replacement and vitamin supplementation with every meal
- High-calorie diet tailored to individual needs
- Regular specialized follow-up at a certified CF center
- Lung transplantation in end-stage disease
Can CF patients have children?
- Men with CF: The vast majority are infertile due to absent or obstructed vas deferens, but can father biological children through sperm retrieval and IVF techniques
- Women with CF: Reduced fertility but many can conceive and carry a pregnancy. Pregnancy should be planned carefully in close consultation with CF and obstetric specialists, as it may temporarily worsen disease symptoms.
Sources and Bibliography
- Lega Italiana Fibrosi Cistica (Italian Cystic Fibrosis League)
- Fondazione per la Ricerca sulla Fibrosi Cistica (Foundation for Cystic Fibrosis Research)
- Mayo Clinic: Cystic Fibrosis – Symptoms and Causes
- NIH – National Heart, Lung, and Blood Institute: Cystic Fibrosis
- Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.
- Middleton PG, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809–1819.
- Cystic Fibrosis Foundation (CFF): About Cystic Fibrosis
- European Cystic Fibrosis Society (ECFS): Clinical Practice Guidelines
- Castellani C, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178.
- Observatoire des Maladies Rares (OSSERVATORIOMALATTIERARE): Fibrosi Cistica – screening neonatale
